Table 2. Survival analyses results according to clinicopathologic parameters in all study subjects.
| No. of patients (%) | Progression-free survival (PFS) | Overall survival (OS) | |||||
|---|---|---|---|---|---|---|---|
| Median PFS (mo) | Univariate analysis p-value | Multivariate analysis adjusted HR (95% CI) | Median OS (mo) | Univariate analysis p-value | Multivariate analysis adjusted HR (95% CI) | ||
| All | 114 (100) | 3.3 | 17.1 | ||||
| Sex | 0.921 | NA | 0.078 | ||||
| Female | 35 (31) | 3.5 | 19.2 | 0.68 (0.23–0.87) | |||
| Male | 79 (69) | 2.8 | 15.4 | Reference | |||
| Age, yr | 0.543 | NA | 0.117 | ||||
| <65 | 59 (52) | 3.7 | 19.7 | 0.98 (0.73–1.93) | |||
| ≥65 | 55 (48) | 2.8 | 14.4 | Reference | |||
| Smoking | 0.427 | NA | 0.197 | ||||
| Never | 38 (33) | 3.6 | 18.2 | 0.94 (0.54–2.10) | |||
| Ever | 76 (67) | 2.9 | 15.0 | Reference | |||
| ECOG performance status | 0.344 | NA | 0.003 | ||||
| 0, 1 | 95 (83) | 3.3 | 21.6 | 0.77 (0.24–0.91) | |||
| ≥2 | 19 (17) | 2.5 | 16.9 | Reference | |||
| T stage | 0.610 | NA | 0.712 | NA | |||
| T1 | 7 (6) | 3.3 | 17.8 | ||||
| ≥T2 | 107 (94) | 2.6 | 15.4 | ||||
| N stage | 0.392 | NA | 0.614 | NA | |||
| N0 | 9 (8) | 3.4 | 17.5 | ||||
| ≥N1 | 105 (92) | 2.8 | 16.0 | ||||
| Stage | 0.267 | 0.041 | |||||
| IIIB | 10 (9) | 4.6 | 0.81 (0.64–0.97) | 19.1 | 0.83 (0.35–0.89) | ||
| IV | 104 (91) | 2.9 | Reference | 13.2 | Reference | ||
| Metastatic organs | 0.039 | 0.344 | NA | ||||
| 0–2 | 72 (63) | 4.3 | 0.84 (0.54–1.40) | 18.7 | |||
| ≥3 | 42 (37) | 2.9 | Reference | 17.1 | |||
| Brain metastasis | 0.687 | NA | 0.373 | NA | |||
| No | 70 (61) | 3.3 | 17.1 | ||||
| Yes | 44 (39) | 3.2 | 16.4 | ||||
| ALK translocation* | 0.307 | NA | 0.483 | NA | |||
| Negative | 45 (83) | 3.3 | 17.5 | ||||
| Positive | 9 (16) | 2.9 | 16.9 | ||||
| KRAS mutation* | 0.042 | 0.590 | NA | ||||
| Negative | 36 (83) | 4.1 | 0.91 (0.34–1.99) | 18.1 | |||
| Positive | 7 (17) | 2.4 | Reference | 14.8 | |||
| Differentiation | 0.318 | NA | 0.721 | NA | |||
| Well | 78 (69) | 3.6 | 18.1 | ||||
| Moderate–poor | 36 (31) | 3.2 | 16.2 | ||||
| Second-line treatment† | 0.519 | NA | 0.049 | ||||
| Yes | 82 (72) | 3.4 | 20.5 | 0.95 (0.31–1.92) | |||
| No | 18 (28) | 3.1 | 15.1 | Reference | |||
| First-line treatment | <0.001 | 0.098 | |||||
| Conventional | 73 (64) | 2.2 | Reference | 16.1 | Reference | ||
| Pemetrexed maintenance | 41 (36) | 5.8 | 0.73 (0.15–0.87) | 22.3 | 0.87 (0.28–2.16) | ||
HR: hazard ratio; CI: confidence interval; NA: not applicable; ECOG: Eastern Cooperative Oncology Group; T: tumor; N: lymph node; ALK: anaplastic lymphoma kinase; KRAS: Kirsten rat sarcoma.
*ALK translocation and KRAS mutation data were available in 54 and 43 patients, respectively. †82 patients received second line treatment.